Virax Biolabs Group Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRAX research report →
Range $1 – $1
Price Chart
About the company
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
- CEO
- James Foster
- IPO
- 2022
- Employees
- 26
- HQ
- Lanarkshire, SC, GB
Get TickerSpark's AI analysis on VRAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $378.85K
- P/E
- -0.08
- PEG
- -0.00
- P/S
- 27.00
- P/B
- 0.11
- EV/EBITDA
- 0.72
- Div Yield
- 0.00%
- Gross Margin
- -1480.46%
- Op Margin
- -64038.24%
- Net Margin
- -52473.24%
- ROE
- -114.24%
- ROIC
- -100.03%
Latest fiscal year · YoY change
- Revenue
- $12.42K+96.2%
- Gross Profit
- $7.69K+114.5%
- Op Income
- $-6,399,730
- Net Income
- $-5,023,750+17.1%
- EPS
- $-12.64+74.2%
- OCF Growth
- -1.3%
- FCF Growth
- +5.6%
- 52W High
- $21.75
- 52W Low
- $1.85
- 50D MA
- $2.71
- 200D MA
- $4.64
- Beta
- 1.39
- RSI (14)
- 36
- Avg Volume
- 1.79M
No earnings-call transcripts are available for VRAX yet.
- Free Float
- 98.2%
- Shares Outstanding
- 19.92M
- Float Shares
- 19.57M
of shares held by institutions
5 13F filers
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | HAIGHT NELSON M | other | 2,000 |
| Mar 18, 26 | HAIGHT NELSON M | other | 10,000 |
| Mar 18, 26 | HAIGHT NELSON M | other | 10,000 |
| Mar 18, 26 | HAIGHT NELSON M | other | 10,000 |
| Mar 18, 26 | McCracken Nigel William | other | 20,000 |
| Mar 18, 26 | McCracken Nigel William | other | 50,000 |
| Mar 18, 26 | McCracken Nigel William | other | 29,416 |
| Mar 18, 26 | Foster James Alexander Cunliffe | other | 0 |
| Mar 18, 26 | Foster James Alexander Cunliffe | other | 37,250 |
| Mar 18, 26 | Foster James Alexander Cunliffe | other | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VRAX coverage
Recent articles, reports, and earnings notes.
No research on VRAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VRAX report →Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
prnewswire.com · Jul 16
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
prnewswire.com · Jul 10
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
prnewswire.com · Jul 9
Why this biotech stock more than tripled on Thursday
invezz.com · Jul 9
Why Did Virax Biolabs Stock Triple In One Session?
benzinga.com · Jul 9
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
prnewswire.com · Jul 9
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
prnewswire.com · Jun 24
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
prnewswire.com · May 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.